Array BioPharma Announces Clinical Data Presentations at the 2012 ASCO Annual Meeting
BOULDER, Colo.--(BUSINESS WIRE)--May 16, 2012 - Array BioPharma Inc. (NASDAQ: ARRY) today announced oral presentations on its two MEK inhibitors, selumetinib (AZD6244) and MEK162 at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting, which will held June 1-5, 2012 at McCormick Place in Chicago, Illinois. Array invented selumetinib and MEK162 and subsequently licensed them to AstraZeneca and Novartis, respectively.
Three oral presentations at ASCO:
Selumetinib
| Title:
|
Phase II double-blind,
randomized study of selumetinib (SEL) plus docetaxel (DOC) versus
DOC plus placebo as second-line treatment for advanced KRAS mutant
non-small cell lung cancer (NSCLC) (Abstract #7503)
|
|||||
| Presenter:
|
Pasi A. Janne, MD, PhD | |||||
| Date:
|
Monday, June 4, 2012, 5:00 – 5:15 p.m. EDT | |||||
| Title:
|
Reacquisition of RAI
uptake in RAI-refractory metastatic thyroid cancers by pretreatment
with the MEK inhibitor selumetinib (Abstract #5509)
|
|||||
| Presenter:
|
Alan L. Ho, MD, PhD | |||||
| Date:
|
Monday, June 4, 2012, 1:00 – 1:15 p.m. EDT | |||||
| MEK162
|
||||||
| Title:
|
Efficacy and safety of
oral MEK162 in patients with locally advanced and unresectable or
metastatic cutaneous melanoma harboring BRAFV600 or NRAS mutations*
(Abstract #8511)
|
|||||
| Presenter:
|
Paolo A. Ascierto, MD | |||||
| Date:
|
Monday, June 4, 2012, 4:45 – 5:00 p.m. EDT | |||||
he abstract submitted for MEK162 does not incorporate data and new
findings generated since the time of submission in early 2012. The
latest and most up-to-date clinical data will be delivered during the
investigator's presentation at the Annual Meeting itself, at the date
and time listed above.
In addition, the following scientific posters on selumetinib and
GDC-0068, an Akt inhibitor partnered with Genentech, will be presented
at the conference.
|
ASCO Abstract Number
|
ASCO Abstract Title |
Presentation Date and Time (EDT)
|
||||||||
| 3529 | Pharmacodynamic biomarker-driven trial of MK-2206, an AKT inhibitor, with AZD6244 (selumetinib), a MEK inhibitor, in patients with advanced colorectal carcinoma (CRC) | Friday,
June 1 2 - 6 pm
|
||||||||
| 3020 | A phase I, single-institution, open-label, dose escalation trial with an expansion cohort evaluating the safety and tolerability of AZD6244 and IMC-A12 in subjects with advanced solid malignancies | Saturday,
June 2 2:15 - 6:15 pm
|
||||||||
| 3021 | A phase Ib study of the Akt inhibitor GDC-0068 with docetaxel (D) or mFOLFOX-6 (F) in patients (pts) with advanced solid tumors | Saturday,
June 2 2:15 – 6:15 pm
|
||||||||
| 8598 | Pharmacodynamic activity of selumetinib to predict radiographic response in advanced uveal melanoma | Sunday,
June 3 9 am - 1 pm
|
||||||||
| 3103 | A phase I study of selumetinib (AZD6244/ARRY-142866) in combination with cetuximab (cet) in refractory solid tumors and KRAS mutant colorectal cancer (CRC) | Monday,
June 4 9 am - 1 pm
|
||||||||
| 4100 | A phase I/II study of AZD6244 in combination with sorafenib (Nexavar - Bayer/Onyx) in advanced hepatocellular carcinoma | Monday,
June 4 9 am - 1 pm
|
||||||||
| TPS2616 | A phase Ib/II study testing the safety and efficacy of combined inhibition of the AKT/PI3K and AR signaling pathways in castration-resistant prostate cancer: GDC-0068 or GDC-0980 with abiraterone acetate versus abiraterone acetate | Monday,
June 4 9 am - 1 pm
|
||||||||
| 6582 | Phase II study of the oral MEK inhibitor selumetinib (AZD6244) in advanced acute myeloid leukemia (AML) | Monday,
June 4 2:15 - 6:15 pm
|
||||||||
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small-molecule drugs to treat patients afflicted with cancer and inflammatory diseases. Array has four core proprietary clinical programs: ARRY-614 for myelodysplastic syndromes, ARRY-520 for multiple myeloma, ARRY-797 for pain and ARRY-502 for asthma. In addition, Array has 10 partner-funded clinical programs including two MEK inhibitors in Phase 2: selumetinib with AstraZeneca and MEK162 with Novartis. For more formation on Array, please go to www.arraybiopharma.com.
Contact: Array BioPharma Inc.
Tricia Haugeto, 303-386-1193
thaugeto@arraybiopharma.com
Posted: May 2012
